Immuneering (IMRX) EPS (Basic) (2020 - 2023)
Historic EPS (Basic) for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$0.55.
- Immuneering's EPS (Basic) fell 942.81% to -$0.55 in Q4 2023 from the same period last year, while for Sep 2024 it was -$0.52, marking a year-over-year increase of 7108.12%. This contributed to the annual value of -$1.93 for FY2023, which is 97.7% down from last year.
- Immuneering's EPS (Basic) amounted to -$0.55 in Q4 2023, which was down 942.81% from -$0.45 recorded in Q3 2023.
- In the past 5 years, Immuneering's EPS (Basic) registered a high of -$0.05 during Q4 2021, and its lowest value of -$1.61 during Q2 2021.
- Moreover, its 4-year median value for EPS (Basic) was -$0.5 (2022), whereas its average is -$0.67.
- Per our database at Business Quant, Immuneering's EPS (Basic) skyrocketed by 9576.27% in 2021 and then crashed by 90000.0% in 2022.
- Immuneering's EPS (Basic) (Quarter) stood at -$1.18 in 2020, then surged by 95.76% to -$0.05 in 2021, then tumbled by 900.0% to -$0.5 in 2022, then decreased by 9.43% to -$0.55 in 2023.
- Its EPS (Basic) was -$0.55 in Q4 2023, compared to -$0.45 in Q3 2023 and -$0.43 in Q2 2023.